Protalix BioTherapeutics (PLX) Share-based Compensation (2010 - 2026)

Protalix BioTherapeutics has reported Share-based Compensation for 17 years, with the latest figure at $398000.0 in Q2 2026.

• On a quarterly basis, Share-based Compensation fell 6.79% year-over-year to $398000.0 in Q2 2026; TTM through Jun 2026 was $3.1 million, a 40.47% increase from a year earlier, with the FY2025 full-year figure at $3.2 million, down 23.06% from the prior year.
• Share-based Compensation was $398000.0 for Q2 2026 at Protalix BioTherapeutics, down from $532000.0 in the prior quarter.
• The five-year high for Share-based Compensation was $8.5 million in Q2 2022, with the low at $81000.0 in Q4 2025.
• Average Share-based Compensation over 5 years is $1.1 million, with a median of $583000.0 recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 2160.05% in 2022, then plunged 97.07% in 2023.
• Over 5 years, Share-based Compensation stood at $539000.0 in 2022, then jumped by 153.62% to $1.4 million in 2023, then tumbled by 52.16% to $654000.0 in 2024, then tumbled by 87.61% to $81000.0 in 2025, then soared by 391.36% to $398000.0 in 2026.
• The last three Share-based Compensation figures came in at $398000.0 (Q2 2026), $532000.0 (Q1 2026), and $81000.0 (Q4 2025), per Business Quant data.